THE SAFETY OF DRUGS FOR MENARINI

Menarini monitors the safety of a drug even after it’s marketed, from the time a drug is prescribed by the physicians up to the time it’s used by the patient (and even later).

This monitoring is done through an essential instrument, Pharmacovigilance, which takes care of identifying, evaluating, understanding and preventing any type of any safety problem that may occur following the use of a drug.

For all the drugs marketed by Menarini in the world, all possible information about any problem resulting from the use of a drug, identified as a possible adverse event, is collected through safety reports.

These reports can be made by healthcare operators (physicians, nurses, pharmacists) or by the patients themselves.

BELGIUM:

Federal Agency for Medicines and Health Products
www.famhp.be
Department Vigilance:
www.eenbijwerkingmelden.be
e-mail:

The NETHERLANDS:

Dutch Side Effects Center Lareb
Website: www.lareb.nl

LUXEMBOURG:

Centre Régional de Pharmacovigilance de Nancy ou Division de la pharmacie et des médicaments de la Direction de la santé
Website: www.guichet.lu/pharmacovigilance